title: Cost-effectiveness analysis in heart disease, Part III: Ischemia, congestive heart failure, and arrhythmias.
abstract: Cost-effectiveness analyses were reviewed in the following diagnostic and treatment categories: acute myocardial infarction (MI) and diagnostic strategies for coronary artery disease (CAD), coronary artery bypass graft (CABG) surgery, percutaneous transluminal coronary angioplasty (PTCA), congestive heart failure (CHF), and arrhythmias. In the case of acute MI, coronary care units, as presently used, are rather expensive but could be made much more efficient with more effective triage and resource utilization; reperfusion via thrombolysis is cost-effective, as are beta-blockers and angiotensin-converting enzyme (ACE) inhibitors post-MI in appropriate patients. Cost-effectiveness of CAD screening tests depends strongly on the prevalence of disease in the population studied. Cost-effectiveness of CABG surgery depends on targeting; eg, it is highly effective for such conditions as left-main and three-vessel disease but not for lesser disease. PTCA appears to be cost-effective in situations where there is clinical consensus for its use, eg, severe ischemia and one-vessel disease, but requires further analysis based on randomized data; coronary stents also appear to be cost-effective. In preliminary analysis, ACE inhibition for CHF dominates, ie, saves both money and lives. Cardiac transplant appears to be cost-effective but requires further study. For arrhythmias, implantable cardioverter defibrillators are cost-effective, especially the transvenous device, in life-threatening situations; radiofrequency ablation is also cost-effective in patients with Wolff-Parkinson-White syndrome apart from asymptomatic individuals; and pacemakers have not been analyzed except in the case of biofascicular block, where results were variable depending on the situation and preceding tests.
authors.affiliation: Department of Medicine, College of Human Medicine, Michigan State University, East Lansing 48824.
authors.forename: J
authors.initials: J
authors.lastname: Kupersmith
authors.forename: M
authors.initials: M
authors.lastname: Holmes-Rovner
authors.forename: A
authors.initials: A
authors.lastname: Hogan
authors.forename: D
authors.initials: D
authors.lastname: Rovner
authors.forename: J
authors.initials: J
authors.lastname: Gardiner
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000191:economics; D000889:Anti-Arrhythmia Agents / Q000191:economics; D001145:Arrhythmias, Cardiac / Q000191:economics* / Q000628:therapy; D017115:Catheter Ablation / Q000191:economics; D001026:Coronary Artery Bypass / Q000191:economics; D003325:Coronary Care Units / Q000191:economics; D003362:Cost-Benefit Analysis; D017147:Defibrillators, Implantable / Q000191:economics; D006333:Heart Failure / Q000191:economics* / Q000628:therapy; D006801:Humans; D017202:Myocardial Ischemia / Q000175:diagnosis / Q000191:economics* / Q000628:therapy; D010138:Pacemaker, Artificial / Q000191:economics; D015912:Thrombolytic Therapy / Q000191:economics
chemical_list: D000889:Anti-Arrhythmia Agents